Search details
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Article
in English
| MEDLINE | ID: mdl-38048557
2.
Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients.
Blood
; 141(9): 1036-1046, 2023 03 02.
Article
in English
| MEDLINE | ID: mdl-36096473
3.
Pro-inflammatory cells sustain leukemic clonal expansion in T-cell large granular lymphocyte leukemia.
Haematologica
; 109(1): 163-174, 2024 Jan 01.
Article
in English
| MEDLINE | ID: mdl-37439335
4.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Article
in English
| MEDLINE | ID: mdl-37439329
5.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Article
in English
| MEDLINE | ID: mdl-38818978
6.
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
Ann Hematol
; 103(1): 125-132, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37731147
7.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica
; 108(3): 833-842, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36200419
8.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35608183
9.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34774221
10.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Article
in English
| MEDLINE | ID: mdl-33739457
11.
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Br J Haematol
; 188(6): 907-917, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31898319
12.
Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia.
Haematologica
; 105(5): 1351-1360, 2020 05.
Article
in English
| MEDLINE | ID: mdl-31467122
13.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Haematologica
; 105(4): 1074-1080, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31248973
14.
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Hematol Oncol
; 38(3): 257-265, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32356913
15.
Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: Suggestive features and diagnostic challenges.
J Peripher Nerv Syst
; 25(3): 312-315, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32627254
16.
Interrogating molecular genetics to refine LGLL classification.
Blood
; 139(20): 3002-3004, 2022 05 19.
Article
in English
| MEDLINE | ID: mdl-35587872
17.
Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.
Ann Hematol
; 98(3): 679-689, 2019 Mar.
Article
in English
| MEDLINE | ID: mdl-30539276
18.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Blood
; 127(9): 1102-8, 2016 Mar 03.
Article
in English
| MEDLINE | ID: mdl-26729895
19.
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.
Qual Life Res
; 27(6): 1545-1554, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29520559
20.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica
; 106(1): 291-294, 2021 01 01.
Article
in English
| MEDLINE | ID: mdl-32107338